CN101548972A - Solid pharmaceutical composition containing repaglinide - Google Patents
Solid pharmaceutical composition containing repaglinide Download PDFInfo
- Publication number
- CN101548972A CN101548972A CNA2008101033261A CN200810103326A CN101548972A CN 101548972 A CN101548972 A CN 101548972A CN A2008101033261 A CNA2008101033261 A CN A2008101033261A CN 200810103326 A CN200810103326 A CN 200810103326A CN 101548972 A CN101548972 A CN 101548972A
- Authority
- CN
- China
- Prior art keywords
- solid composite
- composite medicament
- medicament according
- mixture
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a solid pharmaceutical composition containing repaglinide. The solid pharmaceutical composition can exist in various forms of dispersing tablets, oral disintegrating tablets and capsules and is used for curing the type 2 diabetes of which the high blood sugar cannot be effectively controlled by diet control and exercise.
Description
Technical field
The present invention relates to a kind of solid composite medicament that contains repaglinide, especially a kind ofly be used for the treatment of the repaglinide solid composite medicament that diet control and motion exercise can not effectively be controlled the type 2 diabetes mellitus of hyperglycemia.
Background technology
Repaglinide is a kind of non-sulfonylurea Drugs Promoting Insulin Secretion, 36KDA protein-specific on the potassium-channel of the outer dependency ATP of this product and islet cells film combines, potassium channel is closed, calcium channel is open, flow of calcium ions, promote insulin secretion, it acts on faster than sulfonylurea, so hypoglycemic activity is very fast after the meal.This product is mainly used in the patient that diet control and motion exercise can not effectively be controlled the type 2 diabetes mellitus of hyperglycemia.
WO0121159 discloses the combination medicine of the medicine of a kind of repaglinide or Nateglinide and other treatment diabetes, is used to prevent and treats type 2 diabetes mellitus reach disease or the illness relevant with diabetes.This patent has also been protected the composition and method of making the same of Nateglinide and pharmaceutically acceptable carrier.But the pharmaceutical composition of its protection can only stripping in 30 minutes, and onset is slower.
The invention provides a kind of repaglinide solid composite medicament that can quick acting, can stripping onset within 15 minutes, and be oral cavity disintegration tablet or dispersible tablet, patient's taking convenience.
Summary of the invention
The applicant provides a kind of repaglinide folk prescription oral solid formulation, and is rapid-action, patient's compliance height.
The invention provides a kind of solid composite medicament that contains repaglinide, contain percentage by weight and be 0.1%～10% repaglinide and 80%～99.9% pharmaceutically acceptable auxiliaries.
This solid composite medicament provided by the invention, existence form can be oral cavity disintegration tablet, dispersible tablet.
This solid composite medicament provided by the invention, pharmaceutically acceptable auxiliaries are one or more the mixture in filler, disintegrating agent, binding agent, correctives, the lubricant.
This solid composite medicament provided by the invention, filler are one or more the mixture in lactose, microcrystalline Cellulose, starch, pre-paying starch, mannitol, the calcium hydrogen phosphate.
This solid composite medicament provided by the invention, disintegrating agent are one or more the mixture in polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, swollen speed, the low-substituted hydroxypropyl cellulose sodium.
This solid composite medicament provided by the invention, binding agent are one or more the mixture in water, polyvidone, starch, ethanol, the sodium carboxymethyl cellulose.
This solid composite medicament provided by the invention, correctives are one or more the mixture in sucralose, citric acid, green apple essence, the acrylic resin.
This solid composite medicament provided by the invention, lubricant are a kind of in magnesium stearate, the Pulvis Talci.
This solid composite medicament provided by the invention is mainly used in the type 2 diabetes mellitus that treatment diet control and motion exercise can not effectively be controlled hyperglycemia.
The specific embodiment
The present invention is described in further detail below in conjunction with embodiment, but be not limited to following embodiment.Wherein " % " is meant " weight % ".
Embodiment 1: its existence form is an oral cavity disintegration tablet
Preparation technology: take by weighing repaglinide, microcrystalline Cellulose, sorbitol and low-substituted hydroxypropyl methylcellulose sodium by recipe quantity, mix homogeneously, adopting diameter is the scrobicula stamping of 12mm, pulverize, cross 30 mesh sieve granulate, add flavoring orange essence and magnesium stearate, mixing, tabletting.
Embodiment 2: its existence form is a dispersible tablet
Preparation technology: take by weighing repaglinide by recipe quantity, take by weighing all the other adjuvants except that green apple powdered flavor, magnesium stearate of recipe quantity, cross 80 orders, mixing adds 50% alcohol-water solution and makes binding agent, and the system soft material is crossed 20 mesh sieves and granulated drying, 24 mesh sieve granulate; The magnesium stearate, the green apple essence that add the prescription ratio, mixing, tabletting.
The sample dissolution that embodiment 1 and embodiment 2 make sees the following form:
Embodiment 1 and embodiment 2 sample stripping kilsyth basalts
| 5min | 10min | 15min | 30min | |
| Embodiment 1 | 92％ | 95％ | 100％ | 99％ |
| Embodiment 2 | 93％ | 96％ | 99％ | 99％ |
Claims (9)
1. solid composite medicament that contains repaglinide is characterized in that containing percentage by weight and is 0.1%～10% repaglinide and 80%～99.9% pharmaceutically acceptable auxiliaries.
2. solid composite medicament according to claim 1 is characterized in that existence form can be oral cavity disintegration tablet or dispersible tablet.
3. solid composite medicament according to claim 1 is characterized in that described pharmaceutically acceptable auxiliaries is one or more the mixture in filler, disintegrating agent, binding agent, correctives, the lubricant.
4. solid composite medicament according to claim 3 is characterized in that described filler is one or more the mixture in lactose, microcrystalline Cellulose, starch, pre-paying starch, mannitol, the calcium hydrogen phosphate.
5. solid composite medicament according to claim 3 is characterized in that described disintegrating agent is one or more the mixture in polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, swollen speed, the low-substituted hydroxypropyl cellulose sodium.
6. solid composite medicament according to claim 3 is characterized in that described binding agent is one or more the mixture in water, polyvidone, starch, ethanol, the sodium carboxymethyl cellulose.
7. solid composite medicament according to claim 3 is characterized in that described correctives is one or more the mixture in sucralose, citric acid, green apple essence, the acrylic resin.
8. solid composite medicament according to claim 3 is characterized in that described lubricant is a kind of in magnesium stearate, the Pulvis Talci.
9. solid composite medicament according to claim 1 is mainly used in the type 2 diabetes mellitus that treatment diet control and motion exercise can not effectively be controlled hyperglycemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810103326 CN101548972B (en) | 2008-04-03 | 2008-04-03 | Solid pharmaceutical composition containing repaglinide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810103326 CN101548972B (en) | 2008-04-03 | 2008-04-03 | Solid pharmaceutical composition containing repaglinide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101548972A true CN101548972A (en) | 2009-10-07 |
| CN101548972B CN101548972B (en) | 2012-10-17 |
Family
ID=41153615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810103326 Active CN101548972B (en) | 2008-04-03 | 2008-04-03 | Solid pharmaceutical composition containing repaglinide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101548972B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283813A (en) * | 2011-07-28 | 2011-12-21 | 北京万全阳光医学技术有限公司 | Medicinal composition containing repaglinide and preparation method thereof |
| CN102357085A (en) * | 2011-10-27 | 2012-02-22 | 苏州中化药品工业有限公司 | Stable method for preparing repaglinide compressed tablets |
| CN102743354A (en) * | 2012-07-31 | 2012-10-24 | 南京正科制药有限公司 | Repaglinide tablet and preparation method thereof |
| CN103040772A (en) * | 2012-06-20 | 2013-04-17 | 江苏豪森药业股份有限公司 | Repaglinide dispersible tablet and preparation method thereof |
| CN103690498A (en) * | 2013-12-18 | 2014-04-02 | 北京华禧联合科技发展有限公司 | Preparation method capable of improving stability of repaglinide tablets |
| CN104644446A (en) * | 2013-11-25 | 2015-05-27 | 北京万生药业有限责任公司 | Preparing method of repaglinide medicinal preparation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU777776B2 (en) * | 1999-12-23 | 2004-10-28 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
| NZ560269A (en) * | 2005-03-08 | 2010-12-24 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
| CN1814300A (en) * | 2005-12-01 | 2006-08-09 | 广州中一药业有限公司 | Glinide drug adjuvant composition and method for preparing drug containing same |
-
2008
- 2008-04-03 CN CN 200810103326 patent/CN101548972B/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283813A (en) * | 2011-07-28 | 2011-12-21 | 北京万全阳光医学技术有限公司 | Medicinal composition containing repaglinide and preparation method thereof |
| CN102283813B (en) * | 2011-07-28 | 2017-05-24 | 万全万特制药江苏有限公司 | Medicinal composition containing repaglinide and preparation method thereof |
| CN102357085A (en) * | 2011-10-27 | 2012-02-22 | 苏州中化药品工业有限公司 | Stable method for preparing repaglinide compressed tablets |
| CN103040772A (en) * | 2012-06-20 | 2013-04-17 | 江苏豪森药业股份有限公司 | Repaglinide dispersible tablet and preparation method thereof |
| CN102743354A (en) * | 2012-07-31 | 2012-10-24 | 南京正科制药有限公司 | Repaglinide tablet and preparation method thereof |
| CN104644446A (en) * | 2013-11-25 | 2015-05-27 | 北京万生药业有限责任公司 | Preparing method of repaglinide medicinal preparation |
| CN104644446B (en) * | 2013-11-25 | 2018-02-09 | 北京万生药业有限责任公司 | A kind of preparation method of Repaglinide pharmaceutical preparation |
| CN103690498A (en) * | 2013-12-18 | 2014-04-02 | 北京华禧联合科技发展有限公司 | Preparation method capable of improving stability of repaglinide tablets |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101548972B (en) | 2012-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102076362B (en) | Nicotine lozenge compositions | |
| CN102657629B (en) | Ticagrelor sustained-release tablet system and preparation method thereof | |
| CN101185733B (en) | Jianweixiaoshi orally disintegrating tablets and preparation method | |
| CN101548972B (en) | Solid pharmaceutical composition containing repaglinide | |
| CN101822672A (en) | Compound with metformin and repaglinide, preparation method thereof and application thereof | |
| CN1327838C (en) | Vitamin C oral disintegration tablet and its preparing method | |
| CN101181264A (en) | Pharmaceutical composition taking metformin hydrochloride and vigelegting as active component as well as preparing method and uses thereof | |
| CN101711751A (en) | Febuxostat dispersing tablet preparation and preparation method thereof | |
| CN102631329A (en) | Oral paroxetine disintegrating tablet and preparation process thereof | |
| CN103079569A (en) | Pharmaceutical compositions containing vanoxerine | |
| CN102805746A (en) | Compound pharmaceutical chemical acting on respiratory diseases and preparation process and application thereof | |
| CN102451162A (en) | Olanzapine medicine absorbed through oral mucosa | |
| CN101204394A (en) | Composite containing pioglitazone HCL and repaglinide | |
| CN106137988A (en) | A kind of metronidazole solid preparation and preparation method thereof | |
| CN101167731A (en) | Dispersible tablet containing metformin and glibenclamide and preparation method thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN111202731B (en) | Combined application, medicinal composition and application thereof | |
| CN106421794A (en) | Drug compound for treating type II diabetes and preparation method thereof | |
| CN101234094B (en) | Dipyridamole orally disintegrating tablet | |
| CN109125270B (en) | Solid preparation and preparation method thereof | |
| CN102018801B (en) | Novel digestion promoting tablets and preparation method thereof | |
| CN107693555A (en) | A kind of medicine and purposes for treating diabetes | |
| CN101120928B (en) | Vitamin K1 orally disintegrating tablets preparation and preparation method thereof | |
| CN103371981A (en) | Compound repaglinide-metformin hydrochloride solid quick-release preparation and preparation method and application thereof | |
| CN103156817A (en) | Rizatriptan drug absorbed through mouth mucosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: AVENTIS PHARMA (HAINAN) CO., LTD. Free format text: FORMER OWNER: DEZHONG WANQUAN PHARMACEUTICALS TECH. DEV. CO., LTD., BEIJING Effective date: 20110816 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100097 HAIDIAN, BEIJING TO: 570314 HAIKOU, HAINAN PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110816 Address after: 570314 Nanhai Avenue, Hainan, Haikou, China, No. 279 Applicant after: Beijing D-Venturepharm Technology Development Co., Ltd. Address before: 100097 Beijing city Haidian District Sijiqing Wanquan Zhuang 3 Building Applicant before: Dezhong Wanquan Pharmaceuticals Tech. Dev. Co., Ltd., Beijing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Shifeng Inventor after: Meng Fanjing Inventor before: Meng Fanjing |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: MENG FANJING TO: WANG SHIFENG MENG FANJING |